Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

COHERUS BIOSCIENCES, INC.

(CHRS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sector Update: Health Care Stocks Retreat Premarket Thursday

08/19/2021 | 09:18am EST


ę MT Newswires 2021
All news about COHERUS BIOSCIENCES, INC.
01/13COHERUS BIOSCIENCES : and Junshi Biosciences Expand Immuno-Oncology Collaboration to Inclu..
PU
01/13COHERUS BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Other Events, Fina..
AQ
01/11Shanghai Junshi, Coherus BioSciences Partner to License TIGIT-Targeted Antibody in US, ..
MT
01/10FTSE 100 Closes Down 0.5% Dragged by Housebuilders
DJ
01/10Coherus BioSciences Expands Collaboration With Junshi Biosciences to Cover JS006 Licens..
MT
01/10COHERUS BIOSCIENCES : 2022 JP Morgan Conference Presentation
PU
01/10FTSE Edges Lower, November GDP Data Could Lift Sterling
DJ
01/10Coherus and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include TIGIT-Ta..
AQ
01/10FTSE Flat, Construction Stocks Drop After Grenfell Reports
DJ
01/07Coherus BioSciences Signs $300 Million Credit Facility With Pharmakon Advisors; Shares ..
MT
More news
Analyst Recommendations on COHERUS BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 336 M - -
Net income 2021 -188 M - -
Net cash 2021 84,8 M - -
P/E ratio 2021 -4,52x
Yield 2021 -
Capitalization 1 067 M 1 067 M -
EV / Sales 2021 2,92x
EV / Sales 2022 3,33x
Nbr of Employees 334
Free-Float 87,8%
Chart COHERUS BIOSCIENCES, INC.
Duration : Period :
Coherus BioSciences, Inc. Technical Analysis Chart | CHRS | US19249H1032 | MarketScreener
Technical analysis trends COHERUS BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 13,90 $
Average target price 25,43 $
Spread / Average Target 82,9%
EPS Revisions
Managers and Directors
Denny M. Lanfear Chairman, President & Chief Executive Officer
McDavid Stilwell Chief Financial Officer
Barbara K. Finck Chief Medical Officer
Vladimir Vexler Chief Scientific Officer
Mats Wahlstr÷m Independent Director
Sector and Competitors
1st jan.Capi. (M$)
COHERUS BIOSCIENCES, INC.-12.91%1 067
GILEAD SCIENCES, INC.-1.16%90 027
REGENERON PHARMACEUTICALS-2.58%64 327
VERTEX PHARMACEUTICALS6.58%59 510
WUXI APPTEC CO., LTD.-3.73%52 722
BIONTECH SE-23.97%47 338